April 18, 2019
A California federal judge approved $816,000 in attorney fees and expenses to lead counsel Kessler Topaz as part of a $3.25 million settlement Lion Biotechnologies Inc. will pay to resolve investors' claims the company secretly sponsored news stories to inflate its stock.
October 01, 2018
A proposed investor class told a California federal court on Friday that it has inked a $3.25 million settlement with Lion Biotechnologies Inc. to resolve allegations that the company artificially inflated its stock price by secretly commissioning news stories.
February 16, 2018
A California federal judge has dismissed two of six claims in a proposed class action against Lion Biotechnologies Inc., leaving in place allegations that it artificially inflated its stock price by secretly commissioning news stories but ruling the lead investor hadn't traced his stock purchases to one of Lion's allegedly misleading statements.
June 14, 2017
A battle broke out in California federal court Tuesday over which firm will be named lead counsel in a proposed class action accusing Lion Biotechnologies of artificially inflating its stock price through a promotion scheme involving commissioned news stories.
April 14, 2017
Lion Biotechnologies was hit with a putative class action bringing securities fraud allegations in California federal court on Friday after it settled with the U.S. Securities and Exchange Commission to end allegations it was part of a stock promotion scheme involving commissioned news stories.